原料药 API
具备 GMP / DMF 注册就绪度的原料药（API）与候选药物 · 每条标明用途、适应症与为何值得上线
Listing Logic · Why These Products
This category is not a mere directory listing—each product is selected against the four criteria below and comes with both its 'use' and 'why it is listed' so buyers can quickly assess fit. Products are drawn from Unibest's API & Candidates supply catalog and posted after dual qualification and demand screening.
We prioritize APIs already GMP/DMF-ready that can directly support regulatory filing, avoiding the compliance cost of building from scratch.
We target chronic long-term therapies, (WHO) public-health procurement and specialty must-have scenarios with low, predictable demand volatility.
We include first-in-class mechanisms, first approvals or molecules addressing resistance/unmet need, offering differentiated pricing power.
We also tag the number of linked intermediates—deeper in-house intermediate coverage means higher feasibility for scale-up and cost reduction.
Browse by Indication
Pick a class to see only APIs for that disease areaDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Browse by Patent Expiry
The cliff decides when to act — filter by window firstCompound patent expired — generic sourcing and registration feasible
Cliff approaching — lock in API supply and filing schedule early
Mid-term opportunity — start process development and DMF work
Still on-patent — typically licensing or clinical supply
No expiry on file — request a patent assessment for this molecule
Expiry years are compiled from public sources and estimated on compound patents in major markets (US / EU). They exclude polymorph, process and formulation patents, term extensions and paediatric exclusivity. Values marked indicative are directional; values marked to-verify are inferred from filing era. Actual generic entry timing depends on national patent offices and the Orange Book.
Dapagliflozin Propanediol Monohydrate
Glycemic control in type 2 diabetes; reduces heart-failure hospitalization and slows chronic kidney disease progression
A cornerstone SGLT2 inhibitor spanning diabetes, heart failure and CKD (triple indication) with substantial global demand; GMP/DMF-ready and ideal for driving API sourcing through finished-dose registration.
- CAS
- 960404-48-2
- Therapeutic Area
- Endocrine / Cardio-Renal Metabolism
- Target / Mechanism
- SLC5A2
- Labeled Purity
- 99%+
- Patent scope
- Compound patent in major markets (EU earlier; US incl. paediatric exclusivity to 2025)
Letermovir
Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant
A first-in-class CMV terminase inhibitor replacing older ganciclovir-class agents with a better safety profile; a niche, high-value specialty API with limited competition.
- CAS
- 917389-32-3
- Therapeutic Area
- Anti-infective / Transplant
- Labeled Purity
- 98%+
- Patent scope
- US / EU compound patent
Ruxolitinib
Myelofibrosis and polycythemia vera; topical formulations for vitiligo and atopic dermatitis
A foundational agent in myelofibrosis with continued dermatology indication expansion; long-marketed with rigid, predictable demand, a low-volatility steady product.
- CAS
- 941678-49-5
- Therapeutic Area
- Oncology / Hematology
- Target / Mechanism
- JAK1·JAK2
- Labeled Purity
- 98%+
- Patent scope
- US compound patent incl. term extension (timing differs by market)
Brinzolamide
Lowering intraocular pressure in open-angle glaucoma and ocular hypertension
Glaucoma requires lifelong therapy, sustaining steady demand for ophthalmic API; frequently combined with beta-blockers, enabling fixed-dose combination registration.
- CAS
- 138890-62-7
- Therapeutic Area
- Ophthalmology
- Target / Mechanism
- CA2
- Labeled Purity
- 98%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Articaine
Dental infiltration and conduction anesthesia
The preferred dental local anesthetic, fast-acting and highly diffusive, with consumption tied to global dental visits, a high-frequency consumable API.
- CAS
- 23964-58-1
- Therapeutic Area
- Anesthesia / Dentistry
- Target / Mechanism
- SCN1A·SCN5A·SCN4A·SCN7A·SCN2A·+more
- Labeled Purity
- 98%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Ropivacaine
Surgical anesthesia and postoperative acute pain management (epidural, nerve block)
A long-acting local anesthetic for enhanced-recovery (ERAS) pathways with lower cardiotoxicity than bupivacaine; growth in day-surgery directly lifts volume.
- CAS
- 84057-95-4
- Therapeutic Area
- Anesthesia / Analgesia
- Target / Mechanism
- SCN1A·SCN5A·SCN4A·SCN7A·SCN2A·+more
- Labeled Purity
- 98%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Bilastine
Relief of allergic rhinitis and chronic urticaria symptoms
A non-sedating second-generation antihistamine with seasonal demand and long-term use; suitable for combination with cold remedies and pediatric syrups.
- CAS
- 202189-78-4
- Therapeutic Area
- Allergy
- Target / Mechanism
- HRH1
- Labeled Purity
- 98%+
- Patent scope
- Compound patent in EU major markets
Semaglutide
Glycemic control in type 2 diabetes and weight management; reduces cardiovascular risk
The most consequential molecule in the GLP-1 class, dual-driven by diabetes and obesity with demand far exceeding capacity; a high-barrier peptide API and our top strategic product.
- CAS
- 910463-68-2
- Therapeutic Area
- Endocrine / Metabolism
- Target / Mechanism
- GLP1R
- Labeled Purity
- 99%+
- Patent scope
- China compound patent expires 2026; US / EU to 2031-2033 — wide divergence
Vonoprazan
Reflux esophagitis, gastric ulcer; eradication of Helicobacter pylori with antibiotics
The first marketed P-CAB with stronger, more durable acid suppression and markedly higher H. pylori eradication; especially sizable demand in high-H. pylori Asian markets.
- CAS
- 881681-00-1
- Therapeutic Area
- Gastroenterology / H. pylori
- Target / Mechanism
- ATP4A·ATP4B
- Labeled Purity
- 99%+
- Patent scope
- Japan compound patent; US later
Eliprodil
Exploratory indications: neuropathic pain, post-stroke neuroprotection
A selective NR2B-subtype antagonist with fewer psychotropic side effects than traditional NMDA antagonists, a common tool compound for neuroscience research.
- CAS
- 119431-25-3
- Therapeutic Area
- Neurology
- Labeled Purity
- 99%+
- Patent scope
- 1990s compound patent; expired per 20-yr term estimate — to be verified
Elzasonan
Depressive and anxiety disorders
An NK1-receptor-route candidate for mood disorders; psychiatric drugs have long cycles and rigid demand, offering differentiated mechanistic value.
- CAS
- 361343-19-3
- Therapeutic Area
- Psychiatry / Neurology
- Target / Mechanism
- HTR1B·HTR1D
- Labeled Purity
- 98%+
- Patent scope
- 2000s compound patent; expired per 20-yr term estimate — to be verified
Emapunil
Anxiety and other mood disorders
Modulates neurosteroid synthesis via the TSPO pathway, avoiding benzodiazepine dependence, a non-sedating new direction in anxiolysis.
- CAS
- 226954-04-7
- Therapeutic Area
- Psychiatry / Neurology
- Target / Mechanism
- TSPO
- Labeled Purity
- 98%+
- Patent scope
- 2000s compound patent; expired per 20-yr term estimate — to be verified
Vipadenant
Parkinson's disease; also reverses adenosine-pathway tumor immune evasion
An A2A adenosine-receptor antagonist spanning both neurodegeneration and tumor immunotherapy, a dual-scenario molecule with rising research interest.
- CAS
- 442908-10-3
- Therapeutic Area
- 肿瘤免疫 / 神经
- Target / Mechanism
- ADORA2A
- Labeled Purity
- 99%+
- Patent scope
- 2000s compound patent; expired per 20-yr term estimate — to be verified
Devazepide
Exploratory indications related to gastrointestinal motility and appetite regulation
A classic cholecystokinin-receptor antagonist research molecule, commonly used in basic studies of digestion physiology and appetite regulation.
- CAS
- 103420-77-5
- Therapeutic Area
- Gastroenterology / Metabolism
- Labeled Purity
- 99+%
- Patent scope
- 1990s compound patent; expired per 20-yr term estimate — to be verified
Dexecadotril
Symptomatic treatment of acute diarrhea
An anti-secretory antidiarrheal that does not inhibit intestinal motility and pairs with rehydration, widely used in pediatric acute diarrhea.
- CAS
- 112573-72-5
- Therapeutic Area
- Gastroenterology
- Labeled Purity
- 98%+
- Patent scope
- Cadotril-class older product; compound patent expired
Abacavir hydroxyacetate
Antiretroviral combination therapy for HIV-1 infection
A classic nucleoside reverse-transcriptase inhibitor still anchoring AIDS cocktail therapy; long-term must-have in national public-health procurement.
- CAS
- 1446418-48-9
- Therapeutic Area
- Anti-infective / HIV
- Labeled Purity
- 98%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Methyldopa hydrate
Treatment of hypertension, especially pregnancy-induced hypertension
A long-standing safe choice for pregnancy hypertension, not affecting the fetus and retained by multiple guideline sets; sustained demand as an essential medicine in emerging markets.
- CAS
- 41372-08-1
- Therapeutic Area
- Cardiovascular / Pregnancy
- Target / Mechanism
- ADRA2A·ADRA2C·ADRA2B
- Labeled Purity
- 99%+
- Patent scope
- Compound patent long expired; mature multi-source generic supply
Supply source: Unibest API & Candidates supply catalog, sourced and delivered by Unibest. Therapeutic area, indication and selection rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability is subject to DMF/GMP documentation and the technical agreement confirmed at order.